BACK TO TOP
KSE100
185,543.01
0.00
(0.00%)
KSE100PR
58,284.44
0.00
(0.00%)
ALLSHR
110,883.94
0.00
(0.00%)
KSE30
56,997.99
0.00
(0.00%)
KMI30
261,472.17
0.00
(0.00%)
BKTI
54,074.14
0.00
(0.00%)
OGTI
36,259.38
0.00
(0.00%)
KMIALLSHR
71,138.28
0.00
(0.00%)
PSXDIV20
82,818.87
0.00
(0.00%)
UPP9
64,982.58
0.00
(0.00%)
NITPGI
48,453.08
0.00
(0.00%)
NBPPGI
52,548.84
0.00
(0.00%)
MZNPI
32,149.97
0.00
(0.00%)
JSMFI
49,263.88
0.00
(0.00%)
ACI
26,078.47
0.00
(0.00%)
JSGBKTI
79,079.11
0.00
(0.00%)
HBLTTI
17,898.93
08-01-2026
0.10
(0.00%)
MII30
23,840.64
0.00
(0.00%)
Otsuka Pakistan Limited
PHARMACEUTICALS
Rs.364.29
5.49
(1.53%)
1D
1M
6M
YTD
1Y
3Y
5Y
^ As of Thu, Jan 8, 2026 3:40 PM
REG
DFC
CSF
ODL
Open
361.99
High
382.00
Low
360.00
Volume
56,782
CIRCUIT BREAKER
327.86 — 400.72
DAY RANGE
360.00 — 382.00
52-WEEK RANGE ^
155.62 — 478.89
Ask Price
369.00
Ask Volume
234
Bid Price
359.00
Bid Volume
1,000
LDCP
364.29
VAR
21.50
HAIRCUT
27.50
P/E Ratio (TTM) **
16.48
1-Year Change * ^
114.69%
YTD Change * ^
7.70%

No record found

No record found

No record found

Market data powered by capitalstake.com. Provided by PSX. ** Based on unconsolidated financials
  * Returns not adjusted for payouts
  ^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.

Company Profile

BUSINESS DESCRIPTION

Otsuka Pakistan Limited was incorporated in Pakistan as a public limited company. The Company is engaged in the manufacturing, marketing, and distribution of intravenous infusions and trading in pharmaceutical products, nutritional foods, and medical equipment. The company is an indirect subsidiary of Otsuka Pharmaceutical Company Limited, Japan

KEY PEOPLE
Moin Ur RehmanCEO
Mikio BandoChairperson
Shahab Khalid SubzwariCompany Secretary
ADDRESS

30 - B, Sindhi Muslim Co-Operative, Housing Society, Karachi

WEBSITE

www.otsuka.pk

REGISTRAR

THK Associates (Private) Limited, Plot No. 32-C, Jami Commercial Street 2, D.H.A, Phase-VII, Karachi

AUDITOR

M/s. Yousuf Adil Chartered Accountants

Fiscal Year End

June

Equity Profile

Market Cap (000's)
4,407,909.00
Shares
12,100,000
Free Float
3,025,000
Free Float
25.00%

Announcements

Financial Results
Board Meetings
Others
DateTitleDocument
Oct 30, 2025Transmission of Quarterly Report for the Period Ended September 30, 2025 View   PDF
Oct 28, 2025Financial Results for the quarter ended September 30, 2025 View   PDF
Oct 10, 2025Transmission of Annual Report for the Year Ended June 30, 2025 View   PDF
Aug 27, 2025Financial Results for the Year Ended June 30, 2025 View   PDF
Apr 30, 2025Transmission of Quarterly Report for the Period Ended March 31, 2025 View   PDF
DateTitleDocument
Oct 14, 2025Board of Directors Meeting View   PDF
Oct 3, 2025Notice of 37th Annual General Meeting View   PDF
Aug 13, 2025Board of Directors Meeting View   PDF
Apr 14, 2025Board of Directors Meeting View   PDF
Feb 4, 2025Board of Directors Meeting View   PDF
DateTitleDocument
Jan 6, 2026Change of Company Secretary View   PDF
Jan 5, 2026Disclosure of Material Information View   PDF
Dec 12, 2025Annual maintenance (closure of production) View   PDF
Oct 28, 2025EXTRACTS FROM THE RESOLUTIONS PASSED IN 37TH AGM OF THE COMPANY View   PDF
Oct 22, 2025Corporate Briefing Session 2025 View   PDF

Financials

All numbers in thousands (000's) except EPS

Annual
Quarterly
2025202420232022
Sales3,779,5183,163,8683,035,0852,851,733
Profit after Taxation27,677(4,763)(7,207)231,797
EPS2.29(0.39)(0.60)19.16
Q1 2026Q3 2025Q2 2025Q1 2025
Sales1,076,104884,757972,790810,914
Profit after Taxation120,07912,590166,538(119,685)
EPS9.921.0413.76(9.89)
Data powered by Capital Stake. To provide comparable data, information might have been standardized. The data presented may therefore differ from issuer's annual report and 'as reported' data should be obtained directly from the source issuer. See the Capital Stake Terms of Use.

Ratios

2025202420232022
Gross Profit Margin (%)22.8418.2421.2232.49
Net Profit Margin (%)0.73(0.15)(0.24)8.13
EPS Growth (%)687.1835.00(103.13)(39.99)
PEG0.19(8.58)1.17(0.32)

Payouts

Financial Reports